EnlivenHealth® Launches Enliven360, an Integrated Technology Platform Designed to Transform Patient Engagement, Financial Management and Clinical Services for Retail Pharmacies
EnlivenHealth Also Announces Enhancements to its Industry-leading Patient Engagement Solution, Now Powered by Conversational Technology
RALEIGH, NC (April 19, 2022) – EnlivenHealth, the retail pharmacy solutions division of Omnicell, Inc., today announced the launch of Enliven360, an integrated technology platform that enables pharmacists to manage patient engagement, financial management and clinical services, all in one unified software. EnlivenHealth also announced enhancements to Personalized Communications, its industry-leading patient engagement solution. This patient communications software now features smart conversational technology that automates a uniquely human-like phone experience that is expected to help improve patient adherence and retention while optimizing pharmacy workflows and revenue growth.
The new Enliven360 SaaS technology platform enables convenient single-sign-on access to all of EnlivenHealth’s tools and solutions in one integrated software, that should allow pharmacists to focus their valuable time and efforts on providing personalized care that keeps patients healthy and loyal.
Enliven360 will reduce the number of steps needed to complete key pharmacy tasks, that should free up pharmacists to practice at the top of their license and deliver the kinds of clinical services that are expected improve patient adherence and health outcomes while driving prescription growth and profitability. It is designed to empower pharmacists to:
- Drive better patient engagement and increase satisfaction and retention
- Deliver high-value clinical services such as vaccinations and point-of-care testing
- Optimize financial results so pharmacies can grow and thrive over the long run
- Activate analytics-driven insights, improving patient health outcomes and business results
Harnessing ‘Conversational’ Technology to Power Better Patient Engagement & Health Outcomes
In addition to launching its new Enliven360 technology platform, EnlivenHealth unveiled its enhanced and expanded Personalized Communications solution. This industry-leading communications solution now includes advanced conversational technology powered by natural language understanding. With this fully automated patient engagement technology, patients have 24/7 telephone access to the pharmacy via human-like, conversational navigation, which should provide patients with what they need without having to speak to a pharmacy staff member.
By minimizing the amount of time that staff spends on the phone, our conversational-powered Personalized Communications solution is intended to allow pharmacists to practice at the top of their license. The smart technology that powers Personalized Communications will help pharmacies to prioritize the most valued tasks for their staffs to work on.
Personalized Communications is designed to enable pharmacies and their staffs to:
- Strengthen operational efficiency and streamline pharmacy workflows
- Improve patient health outcomes and increase retention
- Increase pharmacy revenue and profitability
- Enhance pharmacist and staff satisfaction and retention
“Our mission is to continually innovate new digital solutions that are designed to transform the practice and business of retail pharmacy,” said Danny Sanchez, senior vice president and general manager of EnlivenHealth. “We believe Enliven360 and our conversational-powered Personalized Communications solution perfectly exemplify this mission. These solutions are not only expected to help pharmacists to keep patients adherent and healthy, they should also reduce the administrative and operational burdens that challenge pharmacies. As a result, pharmacy staffs should be empowered to provide high-value, revenue-generating services that we believe represent the future of retail pharmacy as an increasingly central player in the healthcare system.”
To learn more about these new EnlivenHealth solutions, download the brochures for Enliven360 and Personalized Communications, or contact us for a personalized demo.
EnlivenHealth builds advanced patient engagement, financial management and population health technology solutions that are designed to enable retail pharmacies and health plans to improve the health of their patients and members, while ensuring the long-term health of their business. With the recent acquisitions of FDS Amplicare and MarkeTouch Media, EnlivenHealth now offers one of the industry’s most comprehensive suite of SaaS technology solutions that should help retail pharmacies and health plans to transform and thrive in this new era of digital-driven healthcare. Currently, more than 50,000 retail pharmacies nationwide deploy EnlivenHealth/FDS Amplicare/MarkeTouch Media technology solutions. EnlivenHealth is a division of Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. To learn more, visit EnlivenHealth.co.
ENLIVENHEALTH is a registered trademark of Omnicell, Inc. or one of its subsidiaries.
Certain statements contained in this press release relate to the expected benefits and objectives of EnlivenHealth’s products and services, including Enliven360 and Personalized Communications (and any implied financial impact in connection with the foregoing). These statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties some of which are beyond our control. These risks and uncertainties include, among other things, (i) risks related to the ongoing COVID-19 pandemic (including new variants of the virus), (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (iv) unfavorable general economic and market conditions or reduction in demand for our solutions, (v) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, (vi) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, (vii) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, and (viii) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.